Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors

1 Jan 2021

Abstract excerpt

Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated great promise for treating cancers with homologous recombination (HR) defects, such as germline BRCA1/2 mutation. Further studies suggest that PARP inhibitors (PARPi) can also exhibit efficacy in HR-competent cancers, by amplifying the DNA damage and inducing immunogenic cell death, and PARPi lead to increasing tumor neoantigen, upregulation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33737855
DOI: 10.1177/1179554921996288

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint InhibitorsPMID 33737855Read ↗

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid TumorsSemantic proximity Read ↗

Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune CheckpointsSemantic proximity Read ↗

The potential of PARP inhibitors in targeted cancer therapy and immunotherapySemantic proximity Read ↗

Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical ImplicationsSemantic proximity Read ↗

Development of PARP and Immune-Checkpoint Inhibitor CombinationsSemantic proximity Read ↗

Update on Combination Strategies of PARP InhibitorsSemantic proximity Read ↗

Recent advancements in PARP inhibitors-based targeted cancer therapySemantic proximity Read ↗

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical ApplicationsSemantic proximity Read ↗

The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancersSemantic proximity Read ↗

Advances and perspectives of PARP inhibitorsSemantic proximity Read ↗

Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancerSemantic proximity Read ↗

PARP inhibition and immunotherapy: a promising duo in fighting cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.